Rock Springs Capital Management’s Summit Therapeutics SMMT Stock Holding History

Rock Springs Capital Management’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.4M	Buy	715,000 +5,000	+0.7%	+$88.7K	0.51%	55
2026 Q1	$13.5M	Hold	710,000	–	–	0.79%	42
2025 Q4	$12.4M	Hold	710,000	–	–	0.64%	46
2025 Q3	$14.7M	Hold	710,000	–	–	0.86%	43
2025 Q2	$15.1M	Sell	710,000 -285,000	-29%	-$6.5M	0.94%	37
2025 Q1	$19.2M	Sell	995,000 -59,000	-6%	-$1.18M	1.1%	33
2024 Q4	$18.8M	Buy	1,054,000 +14,000	+1%	+$271K	0.72%	47
2024 Q3	$22.8M	Buy	+1,040,000	New	+$14.5M	0.74%	48

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Rock Springs Capital Management's SMMT Position: Q2 2026 in Review

Rock Springs Capital Management increased its Summit Therapeutics (SMMT) stake by 0.7% in Q2 2026, buying an estimated $88.7K and bringing the position to 715,000 shares worth $10.4M. The position accounts for 0.51% of the portfolio, ranked #55.

Rock Springs Capital Management first reported a position in SMMT in Q3 2024 and has held it in 8 quarters since. The position peaked at $22.8M in Q3 2024. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Rock Springs Capital Management held 715,000 shares of Summit Therapeutics worth $10.4M as of Q2 2026.
Rock Springs Capital Management bought 5,000 Summit Therapeutics shares in Q2 2026, an estimated $88.7K.
Summit Therapeutics made up 0.51% of Rock Springs Capital Management's portfolio in Q2 2026, its #55 holding.
Rock Springs Capital Management first reported a position in Summit Therapeutics in Q3 2024 and has held it in 8 quarters since.
Rock Springs Capital Management's Summit Therapeutics position peaked at $22.8M in Q3 2024.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Rock Springs Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.